Skip to content
Medical Health Aged Care

$30,000 to be won | QV Healthcare Practitioner Student Scholarship Back For 2024

Ego Pharmaceuticals < 1 mins read

Opening on March 4th 2024, the QV Healthcare Practitioner Student Scholarship will award a total of $30,000 in prize money to undergraduate and postgraduate students in Pharmacy, Medicine or Nursing courses in a bid to further the education of the next generation of Australian healthcare practitioners.

Entrants are asked to complete a short essay related to sensitive skin, an area QV understands well having spent decades specialising in skincare for sensitive and problematic skin. Submissions will be judged by a panel of industry experts including Dr. Fabrizio Spada (Scientific Affairs Manager, Ego Pharmaceuticals), Michelle Privitera (President, Eczema Association of Australasia) and Vivienne Speirs (President, Australian Dermatology Nurses' Association).

QV Skincare, part of the Ego Pharmaceuticals portfolio, has a long and close association with healthcare practitioners since the brand was first founded following a request from the dermatology ward of Melbourne’s iconic Queen Victoria Hospital.

Decades on, the QV brand remains family owned, Australian made, and synonymous with quality and innovation. With over 50 QV products sold in more than 20 nations around the world, QV is proud to be Australia’s #1 recommended sensitive skincare brand by healthcare professionals^, a testament to the trust dermatologists, GPs and pharmacists have in the brand.

The QV Healthcare Practitioner Student Scholarship is open from March 4th until June 27th 2024. Interested parties can enter via www.qvskincare.com.au/scholarship.html

^Fifth Quadrant, Sponsored by Ego Pharmaceuticals, OTC Skincare, n = 374, October 2023.


Contact details:

For all media enquiries, please contact Ego Pharmaceuticals:

Courtney Barlow | courtney.barlow@egopharm.com

Media

More from this category

  • Medical Health Aged Care
  • 16/01/2025
  • 08:41
Mainstay Medical Holdings plc

Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®

ReActiv8® Restorative NeurostimulationTM demonstrated statistically significant and clinically meaningful superiority vs. standard of care in all primary and secondary measures of disability, pain and…

  • Contains:
  • Medical Health Aged Care
  • 16/01/2025
  • 06:05
Royal Australian College of GPs

ADHD reform more urgent in NSW with psychiatrists’ workforce crisis

The Royal Australian College of GPs is urging the New South Wales Government to prioritise reforms to improve access to support and treatment for people with attention deficit hyperactivity disorder (ADHD) from GPs after the mass resignation of psychiatrists. Around 200 psychiatrists in NSW's public health system have submitted their resignations amid an ongoing pay dispute with the state government. RACGP New South Wales Chair Dr Rebekah Hoffman said: “GPs should be able to initiate and prescribe medications for people living with ADHD, and manage their care. Allowing GPs to give more support to people living with ADHD will improve…

  • Medical Health Aged Care
  • 16/01/2025
  • 05:00
GlaxoSmithKline

Local scientific discovery Omjarra (momelotinib) now TGA approved for Australians with rare bone marrow cancer

Embargoed: 06.00am Thursday 16th January 2025, MELBOURNE, AUSTRALIA Omjjara (momelotinib) was discovered by Melbourne scientists in 2005.1 Today’s TGA approval follows its recent FDA approval and makes it one of only a handful of original Australian scientific discoveries to secure both milestones.1-6 Omjjara is a once daily pill indicated to treat disease-related consequences of primary or secondary myelofibrosis including spleen enlargement and moderate to severe anaemia.7 Myelofibrosis is a rare bone marrow cancer with an average survival of 5-7 years.7-8 GSK Australia welcomes the Therapeutic Goods Administration (TGA) approval of Omjjara - a local scientific discovery now providing the first…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.